Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Adaptimmune Therapeutics PLC (ADAP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/10/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Sold 47,702 shares
@ $0.9108, valued at
$43.4k
|
|
| 07/10/2023 |
SC 13G/A
| Matrix Capital Management Company, LP reports a 17.3% stake in Adaptimmune Therapeutics PLC |
| 07/05/2023 |
4
| Hegde Priti (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 226,464 options to buy
@ $0
Granted 109,746 options to buy
@ $0
Granted 152,376 options to buy
@ $0 |
|
| 07/05/2023 |
4
| Allen Andrew R (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 73,212 options to buy
@ $0
Granted 56,868 options to buy
@ $0
Granted 45,348 options to buy
@ $0
Granted 109,746 options to buy
@ $0
Granted 152,376 options to buy
@ $0 |
|
| 07/05/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 736,548 options to buy
@ $0
Granted 1,251,966 options to buy
@ $0
Granted 359,700 options to buy
@ $0
Granted 3,568,026 options to buy
@ $0
Granted 57,846 options to buy
@ $0
Granted 2,715,816 options to buy
@ $0
Granted 2,158,776 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Behbahani Ali (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 933,317 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 981,463 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| Alleva Lawrence M (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 1,077,756 options to buy
@ $0 |
|
| 07/03/2023 |
4
| MOTT DAVID M (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 1,462,927 options to buy
@ $0 |
|
| 07/03/2023 |
4
| Allen Andrew R (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 500,000 options to buy
@ $0 |
|
| 06/29/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/29/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/01/2023 |
4
| Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 200,646 shares
@ $0
Granted 200,647 shares
@ $0
Granted 209,931 shares
@ $0 |
|
| 06/01/2023 |
3
| Menzel Garry E (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC |
| 06/01/2023 |
3
| Hegde Priti (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC |
| 06/01/2023 |
3
| Allen Andrew R (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC |
| 06/01/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin...|
Docs:
|
"CONFIDENTIAL",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Remuneration Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Remuneration Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a d...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Corporate Governance and Nominating Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Corporate Governance and Nominating Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restriction...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Audit Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Audit Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a director. 1. AP...",
"Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded into early 2026 with multiple value creating catalysts Webcast to be held tomorrow, June 2nd at 8 a.m. EDT: https://www.gowebcasting.com/12589" |
|
| 05/30/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/12/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/20/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/18/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 04/05/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 04/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|
|
|